Literature DB >> 25355886

Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia.

Pieter Meysman1, Benson Ogunjimi2, Stefan Naulaerts3, Philippe Beutels4, Viggo Van Tendeloo5, Kris Laukens3.   

Abstract

UNLABELLED: Postherpetic neuralgia (PHN) is the most common complication of herpes zoster and is typified by a lingering pain that can last months or years after the characteristic herpes zoster rash disappears. It is well known that there are risk factors for the development of PHN, such as its association with certain HLA alleles. In this study, previous HLA genotyping results were collected and subjected to a meta-analysis with increased statistical power. This work shows that the alleles HLA-A*33 and HLA-B*44 are significantly enriched in PHN patients, while HLA-A*02 and HLA-B*40 are significantly depleted. Prediction of the varicella-zoster virus (VZV) peptide affinity for these four HLA variants by using one in-house-developed and two existing state-of-the-art major histocompatibility complex (MHC) class I ligand prediction methods reveals that there is a great difference in their absolute and relative peptide binding repertoires. It was observed that HLA-A*02 displays a high affinity for an ∼7-fold-higher number of VZV peptides than HLA-B*44. Furthermore, after correction for HLA allele-specific limitations, the relative affinity of HLA-A*33 and HLA-B*44 for VZV peptides was found to be significantly lower than those of HLA-A*02 and HLA-B*40. In addition, HLA peptide affinity calculations indicate strong trends for VZV to avoid high-affinity peptides in some of its proteins, independent of the studied HLA allele. IMPORTANCE: Varicella-zoster virus can cause two distinct diseases: chickenpox (varicella) and shingles (herpes zoster). Varicella is a common disease in young children, while herpes zoster is more frequent in older individuals. A common complication of herpes zoster is postherpetic neuralgia, a persistent and debilitating pain that can remain months up to years after the resolution of the rash. In this study, we show that the relative affinity of HLA variants associated with higher postherpetic neuralgia risk for varicella-zoster virus peptides is lower than that of variants with a lower risk. These results provide new insight into the development of postherpetic neuralgia and strongly support the hypothesis that one of its possible underlying causes is a suboptimal anti-VZV immune response due to weak HLA binding peptide affinity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355886      PMCID: PMC4300672          DOI: 10.1128/JVI.02500-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.

Authors:  R E HOPE-SIMPSON
Journal:  Proc R Soc Med       Date:  1965-01

Review 2.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses.

Authors:  Jonathan W Yewdell
Journal:  Immunity       Date:  2006-10       Impact factor: 31.745

3.  Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.

Authors:  Malene Erup Larsen; Brian Kornblit; Mette Voldby Larsen; Tania Nicole Masmas; Morten Nielsen; Martin Thiim; Peter Garred; Anette Stryhn; Ole Lund; Soren Buus; Lars Vindelov
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-28       Impact factor: 5.742

4.  HLA alleles are associated with postherpetic neuralgia but not with herpes zoster.

Authors:  Daisuke Sumiyama; Eri F Kikkawa; Yuki F Kita; Harumi Shinagawa; Tomotaka Mabuchi; Akira Ozawa; Hidetoshi Inoko
Journal:  Tokai J Exp Clin Med       Date:  2008-12-20

5.  HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN).

Authors:  A Ozawa; Y Sasao; K Iwashita; M Miyahara; J Sugai; M Iizuka; Y Kawakubo; M Ohkido; T Naruse; T Anzai; N Takashige; A Ando; H Inoko
Journal:  Tissue Antigens       Date:  1999-03

6.  Evolution of cytotoxic T-lymphocyte epitopes in hepatitis B virus.

Authors:  Kristi M Westover; Austin L Hughes
Journal:  Infect Genet Evol       Date:  2006-11-30       Impact factor: 3.342

7.  NetCTLpan: pan-specific MHC class I pathway epitope predictions.

Authors:  Thomas Stranzl; Mette Voldby Larsen; Claus Lundegaard; Morten Nielsen
Journal:  Immunogenetics       Date:  2010-04-09       Impact factor: 2.846

Review 8.  What does epidemiology tell us about risk factors for herpes zoster?

Authors:  Sara L Thomas; Andrew J Hall
Journal:  Lancet Infect Dis       Date:  2004-01       Impact factor: 25.071

9.  HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.

Authors:  Tomer Hertz; Christine M Oshansky; Philippa L Roddam; John P DeVincenzo; Miguela A Caniza; Nebojsa Jojic; Simon Mallal; Elizabeth Phillips; Ian James; M Elizabeth Halloran; Paul G Thomas; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

10.  Conflicting selection pressures target the NS3 protein in hepatitis C virus genotypes 1a and 1b.

Authors:  Stephanie Jiménez Irausquin; Austin L Hughes
Journal:  Virus Res       Date:  2009-11-06       Impact factor: 3.303

View more
  8 in total

1.  Cytomegalovirus seropositivity is associated with herpes zoster.

Authors:  Benson Ogunjimi; Niel Hens; Richard Pebody; Hilde Jansens; Holly Seale; Mark Quinlivan; Heidi Theeten; Herman Goossens; Judy Breuer; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  On the feasibility of mining CD8+ T cell receptor patterns underlying immunogenic peptide recognition.

Authors:  Nicolas De Neuter; Wout Bittremieux; Charlie Beirnaert; Bart Cuypers; Aida Mrzic; Pieter Moris; Arvid Suls; Viggo Van Tendeloo; Benson Ogunjimi; Kris Laukens; Pieter Meysman
Journal:  Immunogenetics       Date:  2017-08-04       Impact factor: 2.846

3.  Immunological evasion of immediate-early varicella zoster virus proteins.

Authors:  Pieter Meysman; Dmitry Fedorov; Viggo Van Tendeloo; Benson Ogunjimi; Kris Laukens
Journal:  Immunogenetics       Date:  2016-03-29       Impact factor: 2.846

Review 4.  Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain.

Authors:  Amelia J McFarland; Muhammad S Yousuf; Stephanie Shiers; Theodore J Price
Journal:  Pain Rep       Date:  2021-01-07

5.  Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.

Authors:  Pieter Meysman; Nicolas De Neuter; Esther Bartholomeus; George Elias; Johan Van den Bergh; Marie-Paule Emonds; Geert W Haasnoot; Steven Heynderickx; Johan Wens; Nele R Michels; Julien Lambert; Eva Lion; Frans H J Claas; Herman Goossens; Evelien Smits; Pierre Van Damme; Viggo Van Tendeloo; Philippe Beutels; Arvid Suls; Geert Mortier; Kris Laukens; Benson Ogunjimi
Journal:  Immunogenetics       Date:  2017-12-01       Impact factor: 3.330

6.  Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster.

Authors:  Benson Ogunjimi; Lander Willem; Philippe Beutels; Niel Hens
Journal:  Elife       Date:  2015-07-11       Impact factor: 8.140

7.  Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox.

Authors:  B Ogunjimi; J Van den Bergh; P Meysman; S Heynderickx; K Bergs; H Jansens; E Leuridan; A Vorsters; H Goossens; K Laukens; N Cools; Viggo Van Tendeloo; N Hens; P Van Damme; Evelien Smits; Ph Beutels
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

8.  HLA-DRB1 Alleles Associated with Lower Leishmaniasis Susceptibility Share Common Amino Acid Polymorphisms and Epitope Binding Repertoires.

Authors:  Nicky de Vrij; Pieter Meysman; Sofie Gielis; Wim Adriaensen; Kris Laukens; Bart Cuypers
Journal:  Vaccines (Basel)       Date:  2021-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.